Predictive role of inflammatory markers for the efficacy of first-line immunotherapy plus chemotherapy in advanced gastric cancer
MLR could serve as a new biomarker to predict the efficacy of first-line ICIs plus chemotherapy in patients with locally advanced or metastatic gastric cancer. And it is helpful to select the candidates for first-line ICIs plus chemotherapy, which is worthy of further study.
Authors
- Jiuang Mao
- Hongjian Lin (ORCID: https://orcid.org/0000-0002-1368-5120)
- Chenming Zhong
- Guanglei Qiao
- Yue Jiang (ORCID: https://orcid.org/0000-0002-8334-0013)
- Zhoufeng Deng
- Jianjun Zhang (ORCID: https://orcid.org/0000-0001-7872-3477)
- Li-Ping Yu
- Lijun Ma (ORCID: https://orcid.org/0000-0002-3042-7588)
- Ying Yuan (ORCID: https://orcid.org/0000-0001-5397-5360)
- Zimei Liu
Institutions
- Shanghai Jiao Tong University (CN)
- Tongren Hospital (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-04-26
- DOI
- https://doi.org/10.1007/s12672-025-01857-0
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Shanghai Jiao Tong University